Institute of Biomedical Research (OTCMKTS:MRES) Stock On Radar After A New Appointment

Bioceutical company Institute of Biomedical Research (OTCMKTS:MRES) which is focused on mental health therapeutic research and in alternative plant-based CBD product, provided a key update on Wednesday. The company announced yesterday that it was pleased to welcome the latest addition to its team, WilnaEksteen. She is going to be designated as a Cardiometabolic Product Developer in the company’s M2Biome Division.

Trading Data

On Wednesday, MRES stock moved down 11.67% to $0.0080 with 8.94K shares, compared to volume of 274.48K shares. The stock moved within a range of $0.0071 – 0.0080 after opening trade at $0.0071.

M2Bio Sciences Appoints Wilna Eksteen as M2Biome Senior Cardiometabolic Product Developer

In that particular role, she will be in charge of helping the division with its recipe and product development initiatives. In addition to that, she will also work on the creation of recipes for the consumer-facing brands from the company Medspresso and Liviana.

In this context, it could well be a good idea for investors to consider taking a closer look at her credentials as a professional. She is a professional dietician and had graduated from the University of Pretoria. She had also spent her community service year at the Steve Biko Academic Tertiary Hospital in Pretoria.

It was there that Eksteen developed a passion for crafting diet practices which where sensible and healthy. The announcement with regards to the joining of a key employee is almost always seen as a significant development. It would be interesting to see if it has an effect on the stock.